X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for X4 Pharmaceuticals, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.738 Greetings and welcome to the X4 Pharmaceuticals fourth quarter and full year 2024 financial 00:00:05.738 -- 00:00:10.003 and operating results conference call. At this time, all participants are in a listen-only 00:00:10.003 -- 00:00:14.328 mode. A question-and-answer session will follow the formal presentation. 00:00:14.328 -- 00:00:18.533 As a reminder, this conference call is being recorded, and it is now my pleasure to turn 00:00:18.533 -- 00:00:21.717 to your host, Dan Ferry from LifeSite Advisors. 00:00:21.717 -- 00:00:22.357 Please begin. 00:00:22.357 -- 00:00:24.357 Thank 00:00:25.401 -- 00:00:28.094 you, Operator, and good morning, everyone. 00:00:28.094 -- 00:00:31.399 Presenting on today's call will be X4's Chief Executive Officer, Dr. 00:00:31.399 -- 00:00:36.186 Paula Regan, and Chief Financial Officer, Adam Mostafa. 00:00:36.186 -- 00:00:40.753 Following prepared remarks by each, we will open the call to your questions, 00:00:40.753 -- 00:00:44.977 and we'll be joined by Chief Commercial Officer, Mark Baldry, 00:00:45.100 -- 00:00:50.428 Chief Medical Officer, Dr. Christoph Arvid Engels, and Chief Operating Officer, 00:00:50.428 -- 00:00:52.929 Mary DiBiase. 00:00:53.153 -- 00:00:57.538 As a reminder on today's call, the company will be making forward-looking statements 00:00:57.538 -- 00:01:01.142 regarding regulatory and product development plans. 00:01:01.142 -- 00:01:04.586 These statements are subject to risks and uncertainties that may cause actual results 00:01:04.586 -- 00:01:07.870 to differ from those forecasted. 00:01:07.870 -- 00:01:13.076 A description of these risks can be found in X4's most recent filings with the SEC, including 00:01:13.076 -- 00:01:19.624 this year's Form 10-K, which is expected to be...